Oncology Institute (NASDAQ:STLN) Shares Unloaded by Sen. Richard Blumenthal

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. (NASDAQ:STLN). In a filing disclosed on October 26th, the Senator disclosed that they had sold between $15,001 and $50,000 in Oncology Institute stock on September 22nd.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/23/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.

Oncology Institute Stock Performance

STLN opened at $6.59 on Wednesday. Oncology Institute, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $7.13. The stock’s 50 day simple moving average is $6.47.

Oncology Institute (NASDAQ:STLN) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $161.28 million for the quarter, compared to analysts’ expectations of $152.80 million. Equities research analysts forecast that Oncology Institute, Inc. will post -0.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Legal & General Group Plc bought a new position in Oncology Institute during the second quarter worth $41,000. Granite Investment Partners LLC acquired a new stake in Oncology Institute in the first quarter worth $46,000. R Squared Ltd increased its stake in Oncology Institute by 42.7% in the first quarter. R Squared Ltd now owns 16,353 shares of the company’s stock valued at $50,000 after purchasing an additional 4,891 shares in the last quarter. AMG National Trust Bank bought a new stake in Oncology Institute in the second quarter valued at $54,000. Finally, Engineers Gate Manager LP bought a new stake in Oncology Institute in the second quarter valued at $67,000. Institutional investors and hedge funds own 36.86% of the company’s stock.

Analysts Set New Price Targets

STLN has been the topic of a number of recent research reports. Weiss Ratings initiated coverage on shares of Oncology Institute in a report on Thursday, August 6th. They set a “sell (d-)” rating on the stock. Needham & Company LLC increased their price objective on Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. BTIG Research increased their price objective on Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Finally, Lake Street Capital assumed coverage on Oncology Institute in a research report on Monday, July 6th. They set a “buy” rating and a $10.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.00.

Insider Activity

In related news, major shareholder Jorey Chernett acquired 12,000 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were bought at an average price of $6.54 per share, with a total value of $78,480.00. Following the transaction, the insider directly owned 10,660,858 shares of the company’s stock, valued at $69,722,011.32. This trade represents a 0.11% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Brad Hively sold 298,853 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $6.51, for a total value of $1,945,533.03. Following the completion of the sale, the director owned 411,976 shares of the company’s stock, valued at approximately $2,681,963.76. This represents a 42.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.40% of the stock is currently owned by corporate insiders.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.